Dr. Berenger Biannic is an Associate Director in Chemistry at ESSA Pharma working on the next generation of treatment for prostate cancer patients. After a postdoc in the Trost Lab at Stanford University, he started his industrial career as a drug discovery scientist at FLX Bio (now RAPT Therapeutics) and led the chemistry efforts on an immuno-oncology program. Berenger joined AbbVie in 2018 and worked on multiple oncology programs in the bRo5 chemical space until 2021. Organic chemist by training, Berenger is passionate about pharmacology and how it helps chemists to design high quality clinical candidates. His free time is devoted to making sure his two young boys don’t injure themselves, cooking exotic food and watching the Office over and over.